CMS coverage decision on anti-amyloid monoclonal antibodies for Alzheimer disease

David Knopman; Mary Sano; Howard H. Feldman

doi:10.1038/s41582-022-00672-3

CMS coverage decision on anti-amyloid monoclonal antibodies for Alzheimer disease

David Knopman, Mary Sano, Howard H. Feldman

Research output: Contribution to journal › Comment/debate

Original language	English
Pages (from-to)	379-380
Number of pages	2
Journal	Nature Reviews Neurology
Volume	18
Issue number	7
DOIs	https://doi.org/10.1038/s41582-022-00672-3
State	Published - Jul 2022

Access to Document

10.1038/s41582-022-00672-3

Cite this

@article{2f246b8748af475881330e5e6dc97117,

title = "CMS coverage decision on anti-amyloid monoclonal antibodies for Alzheimer disease",

author = "David Knopman and Mary Sano and Feldman, {Howard H.}",

note = "Funding Information: D.K. serves on a Data Safety Monitoring Board (DSMB) for the Dominantly Inherited Alzheimer Network (DIAN) study. He served on a data safety monitoring board for a tau therapeutic for Biogen but received no personal compensation. He is an investigator in clinical trials sponsored by Biogen, Lilly Pharmaceuticals and the University of Southern California. He has served as a consultant for Roche, Samus Therapeutics, Magellan Health and Alzeca Biosciences but receives no personal compensation. He receives funding from the NIH. M.S. serves as a consultant for Eisai, Avenir, vTv, Biogen, BioXcel, Hoffman LaRoche, NovoNordisk, Novartis and Merck. She chairs the DSMB for the Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer{\textquoteright}s Disease (SESAD), sponsored by the University of Colorado. She receives funding from the NIH. H.H.F. serves as a member of a DSMB/Data Monitoring Committee for Janssen Research and Development and the Roche/Banner Institute, for which he does not receive personal compensation. He receives grant funding through the University of California San Diego (UCSD) from Biohaven Pharmaceuticals, Annovis (QR Pharma), AC Immune, Vivoryon (Probiodrug) and LuMind Foundation and has service agreements for consulting through UCSanD with Novo Nordisk, Samus Therapeutics, Samumed, Tau Consortium & Rainwater Charitable Foundation and Axon Neurosciences, for which he does not receive personal compensation. He holds grant funding from the NIH and the Canadian Institutes of Health Research.",

year = "2022",

month = jul,

doi = "10.1038/s41582-022-00672-3",

language = "English",

volume = "18",

pages = "379--380",

journal = "Nature Reviews Neurology",

issn = "1759-4758",

publisher = "Nature Publishing Group",

number = "7",

}

TY - JOUR

T1 - CMS coverage decision on anti-amyloid monoclonal antibodies for Alzheimer disease

AU - Knopman, David

AU - Sano, Mary

AU - Feldman, Howard H.

N1 - Funding Information: D.K. serves on a Data Safety Monitoring Board (DSMB) for the Dominantly Inherited Alzheimer Network (DIAN) study. He served on a data safety monitoring board for a tau therapeutic for Biogen but received no personal compensation. He is an investigator in clinical trials sponsored by Biogen, Lilly Pharmaceuticals and the University of Southern California. He has served as a consultant for Roche, Samus Therapeutics, Magellan Health and Alzeca Biosciences but receives no personal compensation. He receives funding from the NIH. M.S. serves as a consultant for Eisai, Avenir, vTv, Biogen, BioXcel, Hoffman LaRoche, NovoNordisk, Novartis and Merck. She chairs the DSMB for the Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer’s Disease (SESAD), sponsored by the University of Colorado. She receives funding from the NIH. H.H.F. serves as a member of a DSMB/Data Monitoring Committee for Janssen Research and Development and the Roche/Banner Institute, for which he does not receive personal compensation. He receives grant funding through the University of California San Diego (UCSD) from Biohaven Pharmaceuticals, Annovis (QR Pharma), AC Immune, Vivoryon (Probiodrug) and LuMind Foundation and has service agreements for consulting through UCSanD with Novo Nordisk, Samus Therapeutics, Samumed, Tau Consortium & Rainwater Charitable Foundation and Axon Neurosciences, for which he does not receive personal compensation. He holds grant funding from the NIH and the Canadian Institutes of Health Research.

PY - 2022/7

Y1 - 2022/7

UR - http://www.scopus.com/inward/record.url?scp=85130264022&partnerID=8YFLogxK

U2 - 10.1038/s41582-022-00672-3

DO - 10.1038/s41582-022-00672-3

M3 - Comment/debate

C2 - 35596071

AN - SCOPUS:85130264022

SN - 1759-4758

VL - 18

SP - 379

EP - 380

JO - Nature Reviews Neurology

JF - Nature Reviews Neurology

IS - 7

ER -